Progranulin in neurodegenerative disease

Trends in Neurosciences

Volumn 37, Issue 7, 2014, Pages 388-398

  Petkau, Terri L ^a   Leavitt, Blair R ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRANULIN; SORTILIN; GRN PROTEIN, HUMAN; SIGNAL PEPTIDE;

DEGENERATIVE DISEASE; ENVIRONMENTAL FACTOR; FAMILIAL DISEASE; FRONTOTEMPORAL DEMENTIA; GENE; GENE EXPRESSION; GENETIC VARIABILITY; LOSS OF FUNCTION MUTATION; MICROGLIA; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGRANULIN GENE; REVIEW; ANIMAL; BRAIN; GENETICS; HUMAN; METABOLISM; MOUSE; NERVE CELL; PATHOLOGY;

ANIMALS; BRAIN; GENETIC VARIATION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NEURODEGENERATIVE DISEASES; NEURONS;

EID: 84903511229     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2014.04.003     Document Type: Review

References (119)

1. Seltman R.E., Matthews B.R. Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. CNS Drug 2012, 26:841-870.
2. Pickering-Brown S.M., et al. Inherited frontotemporal dementia in nine British families associated with intronic mutations in the tau gene. Brain 2002, 125:732-751.
3. Cairns N.J., et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am. J. Pathol. 2007, 171:227-240.
4. Mackenzie I.R., et al. Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol. 2011, 121:207-218.
5. Wilson A.C., et al. TDP-43 in aging and Alzheimer's disease - a review. Int. J. Clin. Exp. Pathol. 2011, 4:147-155.
6. Neumann M., et al. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 2009, 132:2922-2931.
7. Sieben A., et al. The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathol. 2012, 124:353-372.
8. Baker M., et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006, 442:916-919.
9. Cruts M., et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006, 442:920-924.
10. Yu C.E., et al. The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch. Neurol. 2010, 67:161-170.
11. Chiang H.H., et al. Progranulin mutation causes frontotemporal dementia in the Swedish Karolinska family. Alzheimers Dement. 2008, 4:414-420.
12. Mukherjee O., et al. Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia. Hum. Mutat. 2008, 29:512-521.
13. Smith K.R., et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am. J. Hum. Genet. 2012, 90:1102-1107.
14. Seelaar H., et al. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J. Neurol. Neurosurg. Psychiatry 2011, 82:476-486.
15. Galimberti D., Scarpini E. Clinical phenotypes and genetic biomarkers of FTLD. J. Neural Transm. 2012, 119:851-860.
16. Whitwell J.L., Josephs K.A. Recent advances in the imaging of frontotemporal dementia. Curr. Neurol. Neurosci. Rep. 2012, 12:715-723.
17. Bozzali M., et al. Structural brain signature of FTLD driven by Granulin mutation. J. Alzheimers Dis. 2013, 33:483-494.
18. Whitwell J.L., et al. Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN. Neurology 2009, 72:813-820.
19. Mackenzie I.R., et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011, 122:111-113.
20. Josephs K.A., et al. Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J. Neuropathol. Exp. Neurol. 2007, 66:142-151.
21. Hatanpaa K.J., et al. TAR DNA-binding protein 43 immunohistochemistry reveals extensive neuritic pathology in FTLD-U: a midwest-southwest consortium for FTLD study. J. Neuropathol. Exp. Neurol. 2008, 67:271-279.
22. Armstrong R.A., Cairns N.J. A morphometric study of the spatial patterns of TDP-43 immunoreactive neuronal inclusions in frontotemporal lobar degeneration (FTLD) with progranulin (GRN) mutation. Histol. Histopathol. 2011, 26:185-190.
23. Gliebus G., et al. Asymmetric TDP-43 distribution in primary progressive aphasia with progranulin mutation. Neurology 2010, 74:1607-1610.
24. Ghidoni R., et al. Circulating progranulin as a biomarker for neurodegenerative diseases. Am. J. Neurodegener. Dis. 2012, 1:180-190.
25. Capell A., et al. Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. J. Neurosci. 2011, 31:1885-1894.
26. Cenik B., et al. Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J. Biol. Chem. 2011, 286:16101-16108.
27. Boxer A.L., et al. Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimers Dement. 2013, 9:176-188.
28. Gass J., et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum. Mol. Genet. 2006, 15:2988-3001.
29. Rademakers R., et al. Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol. 2007, 6:857-868.
30. McDade E., et al. Similar clinical and neuroimaging features in monozygotic twin pair with mutation in progranulin. Neurology 2012, 78:1245-1249.
31. Van Deerlin V.M., et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat. Genet. 2010, 42:234-239.
32. Lang C.M., et al. Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. J. Biol. Chem. 2012, 287:19355-19365.
33. Chen-Plotkin A.S., et al. TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J. Neurosci. 2012, 32:11213-11227.
34. Finch N., et al. TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology 2010, 76:467-474.
35. van der Zee J., et al. TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain 2011, 134:808-815.
36. Cruchaga C., et al. Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch. Neurol. 2011, 68:581-586.
37. DeJesus-Hernandez M., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011, 72:245-256.
38. Renton A.E., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011, 72:257-268.
39. van Blitterswijk M., et al. C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology 2013, 81:1332-1341.
40. Lashley T., et al. A pathogenic progranulin mutation and C9orf72 repeat expansion in a family with frontotemporal dementia. Neuropathol. Appl. Neurobiol. 2013, 10.1111/nan.12100.
41. Del Bo R., et al. No major progranulin genetic variability contribution to disease etiopathogenesis in an ALS Italian cohort. Neurobiol. Aging 2011, 32:1157-1158.
42. Schymick J.C., et al. Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypes. J. Neurol. Neurosurg. Psychiatry 2007, 78:754-756.
43. Nuytemans K., et al. Progranulin variability has no major role in Parkinson disease genetic etiology. Neurology 2008, 71:1147-1151.
44. Brouwers N., et al. Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology 2008, 71:656-664.
45. Wojtas A., et al. C9ORF72 repeat expansions and other FTD gene mutations in a clinical AD patient series from Mayo Clinic. Am. J. Neurodegener. Dis. 2012, 1:107-118.
46. Brouwers N., et al. Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch. Neurol. 2007, 64:1436-1446.
47. Kelley B.J., et al. Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin. Arch. Neurol. 2010, 67:171-177.
48. Cannon A., et al. Clinicopathologic variability of the GRN A9D mutation, including amyotrophic lateral sclerosis. Neurology 2013, 80:1771-1777.
49. Perry D.C., et al. Progranulin mutations as risk factors for Alzheimer disease. JAMA Neurol. 2013, 70:1-5.
50. Galimberti D., et al. GRN variability contributes to sporadic frontotemporal lobar degeneration. J. Alzheimers Dis. 2010, 19:171-177.
51. Galimberti D., et al. Progranulin gene (GRN) promoter methylation is increased in patients with sporadic frontotemporal lobar degeneration. Neurol. Sci. 2012, 34:899-903.
52. Rademakers R., et al. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum. Mol. Genet. 2008, 17:3631-3642.
53. Rollinson S., et al. No association of PGRN 3'UTR rs5848 in frontotemporal lobar degeneration. Neurobiol. Aging 2011, 32:754-755.
54. Hsiung G.Y., et al. rs5848 polymorphism and serum progranulin level. J. Neurol. Sci. 2011, 300(1-2):28-32.
55. Kamalainen A., et al. GRN variant rs5848 reduces plasma and brain levels of granulin in Alzheimer's disease patients. J. Alzheimers Dis. 2013, 33:23-27.
56. Dickson D.W., et al. Common variant in GRN is a genetic risk factor for hippocampal sclerosis in the elderly. Neurodegener. Dis. 2010, 7(1-3):170-174.
57. Pao W.C., et al. Hippocampal sclerosis in the elderly: genetic and pathologic findings, some mimicking Alzheimer disease clinically. Alzheimer Dis. Assoc. Disord. 2011, 25:364-368.
58. Sleegers K., et al. Progranulin genetic variability contributes to amyotrophic lateral sclerosis. Neurology 2008, 71:253-259.
59. Fenoglio C., et al. Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease. J. Alzheimers Dis. 2009, 18:603-612.
60. Lee M.J., et al. rs5848 variant of progranulin gene is a risk of Alzheimer's disease in the Taiwanese population. Neurodegener. Dis. 2011, 8:216-220.
61. Fenoglio C., et al. Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males. Genes Immun. 2010, 11:497-503.
62. Momeni P., et al. Progranulin (GRN) in two siblings of a Latino family and in other patients with schizophrenia. Neurocase 2010, 16:273-279.
63. Petkau T.L., et al. Progranulin expression in the developing and adult murine brain. J. Comp. Neurol. 2010, 518:3931-3947.
64. Matsuwaki T., et al. Age-dependent changes in progranulin expression in the mouse brain. J. Reprod. Dev. 2010, 57:113-119.
65. Ahmed Z., et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am. J. Pathol. 2010, 177:311-324.
66. Byrnes K.R., et al. Delayed inflammatory mRNA and protein expression after spinal cord injury. J. Neuroinflammation 2011, 8:130.
67. Naphade S.B., et al. Progranulin expression is upregulated after spinal contusion in mice. Acta Neuropathol. 2010, 119:123-133.
68. Moisse K., et al. Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression following axotomy: implications for TDP-43 in the physiological response to neuronal injury. Brain Res. 2009, 1249:202-211.
69. Tanaka Y., et al. Exacerbated inflammatory responses related to activated microglia after traumatic brain injury in progranulin-deficient mice. Neuroscience 2013, 231:49-60.
70. Irwin D., et al. Progranulin (PGRN) expression in ALS: an immunohistochemical study. J. Neurol. Sci. 2009, 276(1-2):9-13.
71. Malaspina A., et al. Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J. Neurochem. 2001, 77:132-145.
72. Philips T., et al. Microglial upregulation of progranulin as a marker of motor neuron degeneration. J. Neuropathol. Exp. Neurol. 2010, 69:1191-1200.
73. Revuelta G.J., et al. Association between progranulin and beta-amyloid in dementia with Lewy bodies. Am. J. Alzheimers Dis. Other Demen. 2008, 23:488-493.
74. Gliebus G., et al. Progranulin and beta-amyloid distribution: a case report of the brain from preclinical PS-1 mutation carrier. Am. J. Alzheimers Dis. Other Demen. 2009, 24:456-460.
75. Pereson S., et al. Progranulin expression correlates with dense-core amyloid plaque burden in Alzheimer disease mouse models. J. Pathol. 2009, 219:173-181.
76. Vercellino M., et al. Progranulin expression in brain tissue and cerebrospinal fluid levels in multiple sclerosis. Mult. Scler. 2011, 17:1194-1201.
77. Chen-Plotkin A.S., et al. Brain progranulin expression in GRN-associated frontotemporal lobar degeneration. Acta Neuropathol. 2010, 119:111-122.
78. Wang M., et al. Progranulin overexpression predicts overall survival in patients with glioblastoma. Med. Oncol. 2012, 29:2423-2431.
79. Toh H., et al. Structure, function, and mechanism of progranulin; the brain and beyond. J. Mol. Neurosci. 2011, 45:538-548.
80. Suh H.S., et al. Regulation of progranulin expression in human microglia and proteolysis of progranulin by matrix metalloproteinase-12 (MMP-12). PLoS ONE 2012, 7:e35115. 10.1371/journal.pone.0035115.
81. Chitramuthu B.P., et al. Progranulin modulates zebrafish motoneuron development in vivo and rescues truncation defects associated with knockdown of Survival motor neuron 1. Mol. Neurodegener. 2010, 5:41.
82. Laird A.S., et al. Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. PLoS ONE 2010, 5:e13368. 10.1371/journal.pone.0013368.
83. Ryan C.L., et al. Progranulin is expressed within motor neurons and promotes neuronal cell survival. BMC Neurosci. 2009, 10:130.
84. Van Damme P., et al. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J. Cell Biol. 2008, 181:37-41. jcb.200712039 [pii]. 10.1083/jcb.200712039.
85. Gao X., et al. Progranulin promotes neurite outgrowth and neuronal differentiation by regulating GSK-3beta. Protein Cell 2010, 1:552-562.
86. Tapia L., et al. Progranulin deficiency decreases gross neural connectivity but enhances transmission at individual synapses. J. Neurosci. 2011, 31:11126-11132. 31/31/11126 [pii]. 10.1523/JNEUROSCI.6244-10.2011.
87. Gass J., et al. Progranulin regulates neuronal outgrowth independent of sortilin. Mol. Neurodegener. 2012, 7:33.
88. Petkau T.L., et al. Synaptic dysfunction in progranulin-deficient mice. Neurobiol. Dis. 2012, 45:711-722.
89. Neumann M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
90. Guo A., et al. Progranulin deficiency leads to enhanced cell vulnerability and TDP-43 translocation in primary neuronal cultures. Brain Res. 2010, 1366:1-8.
91. Kleinberger G., et al. Increased caspase activation and decreased TDP-43 solubility in progranulin knockout cortical cultures. J. Neurochem. 2010, 115:735-747.
92. Zhang Y.J., et al. Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J. Neurosci. 2007, 27:10530-10534.
93. Dormann D., et al. Proteolytic processing of TAR DNA binding protein-43 by caspases produces C-terminal fragments with disease defining properties independent of progranulin. J. Neurochem. 2009, 110:1082-1094.
94. Shankaran S.S., et al. Missense mutations in the progranulin gene linked to frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions reduce progranulin production and secretion. J. Biol. Chem. 2008, 283:1744-1753.
95. Yin F., et al. Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB J. 2010, 24:4639-4647.
96. Wils H., et al. Cellular ageing, increased mortality and FTLD-TDP-associated neuropathology in progranulin knockout mice. J. Pathol. 2012, 228:67-76.
97. Colombrita C., et al. TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells. J. Biol. Chem. 2012, 287:15635-15647.
98. Hu F., et al. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 2010, 68:654-667.
99. Zheng Y., et al. C-terminus of progranulin interacts with the beta-propeller region of sortilin to regulate progranulin trafficking. PLoS ONE 2011, 6:e21023. 10.1371/journal.pone.0021023.
100. De Muynck L., et al. The neurotrophic properties of progranulin depend on the granulin E domain but do not require sortilin binding. Neurobiol. Aging 2013, 34:2541-2547.
101. Petoukhov E., et al. Activity-dependent secretion of progranulin from synapses. J. Cell Sci. 2013, 126:5412-5421.
102. Kocerha J., et al. Altered microRNA expression in frontotemporal lobar degeneration with TDP-43 pathology caused by progranulin mutations. BMC Genomics 2011, 12:527.
103. Kim J.Y., et al. Umbilical cord blood mesenchymal stem cells protect amyloid-beta42 neurotoxicity via paracrine. World J. Stem Cells 2012, 4:110-116. 10.4252/wjsc.v4.i11.110.
104. Almeida S., et al. Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. Cell Rep. 2012, 2:789-798.
105. Tao J., et al. Neuroprotective effects of progranulin in ischemic mice. Brain Res. 2012, 1436:130-136.
106. Martens L.H., et al. Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. J. Clin. Invest. 2012, 122:3955-3959.
107. Petkau T.L., et al. Sensitivity to neurotoxic stress is not increased in progranulin-deficient mice. Neurobiol. Aging 2013, 34:2548-2550.
108. Yin F., et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J. Exp. Med. 2010, 207:117-128.
109. Pickford F., et al. Progranulin is a chemoattractant for microglia and stimulates their endocytic activity. Am. J. Pathol. 2011, 178:284-295.
110. Zhu S., et al. Progranulin promotes activation of microglia/macrophage after pilocarpine-induced status epilepticus. Brain Res. 2013, 1530:54-65.
111. Kao A.W., et al. A neurodegenerative disease mutation that accelerates the clearance of apoptotic cells. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:4441-4446.
112. Filiano A.J., et al. Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice. J. Neurosci. 2013, 33:5352-5361.
113. Ghoshal N., et al. Core features of frontotemporal dementia recapitulated in progranulin knockout mice. Neurobiol. Dis. 2012, 45:395-408.
114. Kayasuga Y., et al. Alteration of behavioural phenotype in mice by targeted disruption of the progranulin gene. Behav. Brain Res. 2007, 185:110-118.
115. Crawley J.N. Behavioral phenotyping strategies for mutant mice. Neuron 2008, 57:809-818.
116. Shacka J.J. Mouse models of neuronal ceroid lipofuscinoses: useful pre-clinical tools to delineate disease pathophysiology and validate therapeutics. Brain Res. Bull. 2012, 88:43-57.
117. Kollmann K., et al. Cell biology and function of neuronal ceroid lipofuscinosis-related proteins. Biochim. Biophys. Acta 2013, 1832:1866-1881.
118. Belcastro V., et al. Transcriptional gene network inference from a massive dataset elucidates transcriptome organization and gene function. Nucleic Acids Res. 2011, 39:8677-8688.
119. Tolkatchev D., et al. Structure dissection of human progranulin identifies well-folded granulin/epithelin modules with unique functional activities. Protein Sci. 2008, 17:711-724.